Angiotensin II antagonists in systolic blood pressure control.
Control of systolic blood pressure should be the primary goal of treatment as it is increasingly recognized as a major determinant of cardiovascular risk. Better control offers enormous potential benefits. Effective treatment is desirable but difficult to achieve. All antagonists, particularly eprosartan, are likely to have an increasingly important role in management strategies.
McInnes
G T
GT
Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow G11 6NT.
D000179:Acrylates / Q000627:therapeutic use; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D003695:Delivery of Health Care; D006801:Humans; D006973:Hypertension / Q000517:prevention & control*; D007093:Imidazoles / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects; D013599:Systole; D013876:Thiophenes
D000179:Acrylates; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; D000804:Angiotensin II; C068373:eprosartan